Analyst Ratings for Rocket Pharmaceuticals (RCKT)
RCKT Rating Summary
RCKT Price Target Summary
- Highest: $15.00 (Cantor Fitzgerald)
- Lowest: $3.00 (Goldman Sachs)
- Average: $8.50
* Over Last 12-Mos
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$8.50 (+153.7%)
* Over Last 12-Mos
Rating Score: 6 / 10
Percentile Rank: 63%
Avg. $ Target:
$8.50 (+153.7%)
* Over Last 12-Mos
Rating Score: 6 / 10
Percentile Rank: 63%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 12/19/2025 | TD Cowen | Tara Bancroft | New Coverage | Hold (N/A) |
N/A (N/A) |
3.27 (3.35) |
2.45% | Details |
| 11/18/2025 | JPMorgan | Eric Joseph | Downgrade | Underweight (Neutral) |
N/A (N/A) |
3.04 (3.35) |
10.2% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
